There is currently increased focus on improved understanding of how dendritic cell tolerogenicity is determined and maintained, and on their therapeutic potential. We review recent progress in profiling of regulatory dendritic cells (DCreg), innovative approaches to enhancing dendritic cell tolerogenicity in situ, ex-vivo generation of DCreg and initial clinical testing of these cells in organ transplantation.
INTRODUCTION
Dendritic cells are a heterogeneous group of bone marrow-derived professional antigen-presenting cells (APC) that promote self-tolerance in the healthy steady-state [1] and regulate innate and adaptive immunity [2, 3] . There is, therefore, a strong rationale for targeting dendritic cells in situ or for using dendritic cells as cellular therapies to improve long-term outcomes in organ transplantation. Challenges to optimizing these approaches induce the diversity and plasticity of dendritic cells, incomplete understanding of the molecular pathways that induce a stable, enduring regulatory profile, establishing optimal strategies for selective targeting of dendritic cells in vivo, ex-vivo generation of regulatory dendritic cells (DCreg), combination of DCreg therapy with appropriate immunosuppressive agents, and clinical trial design.
Human dendritic cells comprise multiple subsets, that is, CD141 þ (cDC1) and CD1c þ (cDC2) myeloid cells that originate from a common dendritic cell precursor [4] , inflammatory dendritic cells that differentiate from monocytes under inflammatory conditions, and nonconventional CD123 ], as have methods and protocols for the ex-vivo generation of human DCreg and their mechanisms of tolerance induction [16] . Some of these protocols have been incorporated into clinical trials, but with no current consensus regarding the optimal approach [17 & ]. Herein, we consider recent developments in DCreg profiling, targeting, and use of DCreg as therapeutic agents in transplantation.
TRANSCRIPTIONAL PROFILING/ SIGNATURES OF REGULATORY DENDRITIC CELLS
Intracellular pathways and transcriptional regulators that determine DCreg differentiation and function are poorly understood and few attempts have been made to better comprehend DCreg biology based on transcriptomic or proteomic (omics) profiles. Studies to date (reviewed by Schinnerling et al. [18] ) indicate that tolerogenic properties of dendritic cells emerge as the result of a specific transcriptional program rather than from the retention of an immature state. The transcription factor, interferon regulatory factor 4, promotes regulatory T cell (Treg) generation by augmenting expression of genes required for antigen presentation, together with those that promote T-cell tolerance [14 && ]. Further, omics studies are needed to define which molecules induce a regulatory profile and can therefore be targeted to render dendritic cells tolerogenic and enhance their stability, longevity, and resistance to pro-inflammatory stimuli for therapeutic application. Investigation has been hampered by the fact that many different protocols that target distinct signaling pathways are used to generate DCreg, for example, use of interleukin 10 (IL-10), transforming growth factor (TGF) b, vitamin (Vit) D3, or dexamethasone (Dex), or a combination of IL-10 or Dex with a stimulatory agent, such as the Toll-like receptor (TLR) 4 agonist bacterial lipopolysaccharide or CD40L. Recently, Garcia-Gonzalez et al. [19, 20] examined the transcriptional profile of human monocyte-derived DCreg generated with Dex and activated with the clinically-used TLR4 agonist monophosphoryl lipid A (MPLA). Dex and MPLA jointly induced a distinct transcriptional profile in dendritic cells characterized by the activation of tolerance-associated genes and suppression of inflammatory genes, conferring the potential to regulate immune responses. The pathways that showed greatest regulation were those involving cellular chemotactic responses, cell-cell signaling and interaction, as well as zinc and reactive oxygen species metabolism, favoring the recruitment and proliferation of Treg, whereas suppressing effector Tcell responses. This and other recent innovative strategies to promote DCreg function discussed below are depicted in Fig. 1 .
IN-VIVO FUNCTION OF INFUSED AND ENDOGENOUS REGULATORY DENDRITIC CELLS IN ORGAN TRANSPLANTATION TOLERANCE
The therapeutic effect of pretransplant infusion of donor-derived DCreg in heart-allografted mice does not appear to depend on the in-vivo persistence of intact donor DCreg [21] that are likely killed by host natural killer (NK) cells, but on the function of quiescent, conventional host dendritic cells in secondary lymphoid organs (SLO). Indeed, as shown by Morelli et al. [22] , deletion of host dendritic cells prevents the therapeutic effect of donor-derived DCreg. Host dendritic cells acquire donor major histocompatibility complex (MHC) antigen via the direct pathway of allorecognition by cross-dressing [23, 24] or via the indirect pathway by antigen transfer from the donor DCreg (cross-presentation) [25 & ] (Fig. 2) . A role for donor-derived microvesicles (exosomes) released by the donor DCreg and acquired by host dendritic cells may be an advantage, as it amplifies the effect of the infused DCreg. Consequently, T-cell activation is reduced, indirect pathway T-cell deletion occurs, CD4 þ T cell-B cell help is impaired, and antidonor antibody production is suppressed [26] . Independence of the immune regulatory effect of donorderived DCreg on their persistence following systemic administration offers a potential advantage over other cell therapy approaches (e.g., infusion of Treg) the success of which may depend on in-vivo
KEY POINTS
Omics studies indicate that tolerogenic properties of DCreg arise as the result of a specific transcriptional program.
Dendritic cell-directed targeting of nanovesicles bearing immune regulatory molecules (nanocarriers) can trigger tolerance-promoting mechanisms.
Innovative ex-vivo modifications of dendritic cells can enhance both their immune regulatory function and migration to secondary lymphoid tissue.
Cross-dressing of host dendritic cells has been implicated in organ transplant tolerance.
Clinical testing of DCreg has begun in renal and liver transplantation.
persistence/replication/function of the adoptivelytransferred cells. Also, DCreg have the important ability to regulate CD4 þ and CD8 þ memory T-cell (Tmem) responses [27] [28] [29] [30] -a major barrier to longterm allograft survival in humans.
In both preclinical (mouse) and clinical studies, total lymphoid irradiation and antithymocyte globulin administration promote hematopoietic cell chimerism and tolerance in organ transplant recipients. In studying the mechanistic basis of these effects, Hongo et al. [31 & ] have established that CD8 þ dendritic cells are likely responsible for the initiation of tolerance induction as they ingest apoptotic cells and suppress antidonor T-cell responses via mechanisms including indoleamine dioxygenase production. Moreover, reciprocal interactions between CD8 þ dendritic cells and invariant NKT cells were required for tolerance induction.
THE ROLE OF CROSS-DRESSING OF HOST DENDRITIC CELLS IN ORGAN TRANSPLANT TOLERANCE
Cross-dressing has only recently been implicated in the instigation of transplant tolerance. Thus, Ono et al. [32 && ] have investigated the role of graft-infiltrating, cross-dressed dendritic cells in mouse fully MHC-mismatched liver transplant tolerance that occurs without use of immunosuppressive agents [33] . Although donor interstitial dendritic cells diminished rapidly following liver transplantation, they were replaced in the graft by host dendritic cells that peaked on postoperative day 7 and persisted indefinitely. About 60% of these recipient dendritic cells displayed donor MHC class I, indicating crossdressing. By contrast, only a very minor fraction (0-2%) of cross-dressed dendritic cells (CD-DC) was evident in the spleen. CD-DC sorted from the liver grafts expressed much higher levels of the T-cell coinhibitory molecule programmed death ligand 1 (PD-L1) and high levels of anti-inflammatory IL-10 compared with graft non-CD-DC. Concomitantly, high incidences of programmed death protein 1 (PD-1) hi , T-cell immunoglobulin, and mucin domain containing-3 (TIM-3) þ exhausted graftinfiltrating CD8 þ T cells were observed. Importantly, unlike non-CD-DC, the CD-DC did not stimulate proliferation of allogeneic T cells, but markedly suppressed antidonor host T-cell proliferation. CD-DC were much less evident in allografts from donors lacking the transmembrane adaptor protein DNAX-activating protein of 12 kDa that are rejected acutely [34] . These findings suggest that graft-infiltrating PD-L1
hi CD-DC play a key role in the regulation of alloimmunity and induction of liver transplant tolerance.
Cross-dressing of host dendritic cells has also been implicated in allospecific tolerance in a different context. Thus, maternal hematopoietic microchimerism, that has been linked to the development of allospecific tolerance, has been shown recently [35 && ] to be associated with membrane alloantigen acquisition by host dendritic cells. In the mouse model examined, cross-dressing was associated with enhanced expression of PD-L1 on myeloid dendritic cells and reduced presentation of allopeptide and self-MHC complexes together with increased PD-L1 on plasmacytoid dendritic cells that was associated with PD-L1-dependent CD4 þ T cell anergy. Thus, acquisition of exosomes bearing alloantigen by host dendritic cells may provide an important link between microchimerism and the induction of tolerance.
INNOVATIVE APPROACHES TO IN-SITU TARGETING OF DENDRITIC CELLS
Prolonged ischemia enhances dendritic cell maturation and potentiates adaptive immunity. In the postischemic period, CD4
þ T cells recruited to the liver are closely associated with hepatic dendritic cells. Using 2-photon intravital microscopy together with confocal microscopy, Funken et al. [36] have shown that in-situ targeting of hepatic dendritic cells with a VitD analog (paricalcitol) attenuates their maturation, promotes their tolerogenicity, and ameliorates CD4 þ Th1 cell responses postischemia. This beneficial effect was abolished by blocking dendritic cell-T cell interactions mediated by the cell surface glycoprotein CD44. In a recent report, Zheng et al. [37] found that injected exosomes derived from dendritic cells could attenuate ischemia-reperfusion injury by modulating the balance between Treg and Th17 cells.
Important pathways and molecular mechanisms that regulate peripheral tolerance are being uncovered by combining methods that target delivery of defined T-cell antigens to dendritic cells in vivo with genetic modification of the dendritic cells [15 & ]. These approaches are determining the roles of specific immunomodulatory pathways and different dendritic cell subsets in maintaining immunological tolerance. In a recent example, Reeves et al. [38] have shown that APC-targeted expression of proinsulin coverts insulin-specific CD8 þ T cell priming to tolerance in autoimmune-prone, nonobese diabetic mice. This shift in T-cell priming to tolerance exemplifies the tolerogenic capacity of autoantigen expression by APC in situ and the ability to overcome defects in pathways controlling peripheral tolerance.
Nanoparticle-based drug delivery systems that enable directed, cell type-specific targeting in vivo in combination with delivery of multiple drugs in a single formulation have emerged as a promising approach to dendritic cell-based immunotherapy. Receptors that have been used to target dendritic cells include DEC205 (CD205), CD11c, dendritic cell-specific intracellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), the mannose receptor, Fc receptors, and CD40. Although most approaches have focused on induction of immunity in the context of tumor immunotherapy, nanoparticle delivery is also a promising approach to induce dendritic cells with tolerogenic capacity. Thus, polymeric synthetic nanoparticles (nanocarriers) that target dendritic cells induce stable antigen (ovalbumin)-specific tolerance by delivery of rapamycin [39] . Recently, biodegradable porous silicon nanoparticles displaying anti-DC-SIGN and loaded with rapamycin were shown [40 & ] to target and be taken up more efficiently (compared with isotype-coated nanoparticles) by myeloid dendritic cells in human blood. Moreover, dendritic cell preconditioning with the rapamycin-loaded nanoparticles suppressed allogeneic T-cell proliferation. Notably, Clemente-Casares et al. [41] have shown that systemic delivery of nanoparticles coated with autoantigen bound to MHC II molecules triggers in-vivo expansion of antigen-specific type-1 Treg that, in turn, inhibit autoantigen-loaded APCs and drive differentiation of regulatory B cells in experimental autoimmune disease.
EX-VIVO GENERATION OF REGULATORY DENDRITIC CELLS
Myeloid dendritic cells with tolerogenic properties can be generated readily from bone marrow precursors or blood monocytes in response to granulocyte-macrophage colony-stimulating factor AE IL-4, with addition of one or more pharmacologic/ biologic agents that stably inhibit their maturation and promote their tolerogenicity [42] . These agents include anti-inflammatory cytokines (IL-10; TGFb), antisense oligonucleotides-targeting costimulatory molecules, anti-inflammatory/immunosuppressive drugs [calcineurin inhibitors (CNI), rapamycin, mycophenolate mofetil (MMF), corticosteroids], VitD3 and cyclic AMP inducers, in particular prostaglandin E2. Currently, there is no consensus as to the optimal agent(s) or combination of agents to use for generation of clinical grade DCreg. Phenotypic characteristics of DCreg include low levels of MHC class I and II and T cell costimulatory molecule (CD80; CD86) expression and enhanced expression of T cell coinhibitory (e.g., PD-L1) and death-inducing ligands (e.g., FasL). Their functional characteristics include low secretion of bioactive IL-12p70 and comparatively high levels of anti-inflammatory cytokine (IL-10; TGFb) production. In addition, DCreg can expand or induce the de novo generation of Treg [10, 43, 44] .
An important consideration regarding generation of DCreg is their ability to migrate to SLO. Genetic modification of dendritic cells to enhance their tolerogenic function and promote their in-vivo migration to SLO has been documented [45] [46] [47] . In a more recent study, Dong et al. [48] co-transfected donor-derived immature dendritic cells with an adenovirus bearing the chemokine receptor type 7 (CCR7) gene and a small interfering RNA targeting the nuclear factor-kB transcription factor subunit RelB to concurrently overexpress CCR7 and downregulate RelB expression. The cotransfected cells displayed enhanced migratory ability, resistance to apoptosis, and enhanced ability (compared with CCR7 or RelB knockdown alone) to upregulate Treg and improve mouse skin allograft survival, suggesting that this might be a promising approach in skin (including vascularized composite allograft) transplantation. In a related study, Xin et al. [49 & ] reported that overexpression of CCR7 and BTLA (B and T lymphocyte attenuator, an immunoglobulin superfamily coinhibitory receptor similar structurally to PD-1 and CTLA4) in immature mouse dendritic cells enhanced their tolerogenic function and migration to the SLO chemokine CCL19.
The potential of donor-derived DCreg generated from (murine) induced pluripotential stem cells (iPSC) to function as therapeutic cellular vaccines to generate Treg and induce donor-specific tolerance has been examined recently by Cai et al. [50 & ]. Mouse heart allografts were accepted permanently in a donor-specific manner, accompanied by differentiation of donor-specific CD4 þ Treg, illustrating the promising potential of iPSC-DCreg.
REGULATORY DENDRITIC CELL SUBSETS FOR THERAPEUTIC APPLICATION
Human IL-10-modulated dendritic cells (IL-10 DC) [51] that potently induce Treg [52] have been the focus of research on DCreg for many years. A recent report by Kryczanowsky et al. [53 && ] identified two populations of human monocyte-derived IL-10 DC with tolerogenic properties -CD83 hi CCR7 þ IL-10 DC and CD83 lo CCR7 À IL-10 DC. The CD83 hi CCR7 þ IL-10 DC generated more potently suppressive CD4
þ Treg, exhibited efficient CCR7-directed migration (toward the SLO chemokine CCL21) and retained stable function under inflammatory conditions, thus satisfying important criteria for prospective clinical application.
DONOR VERSUS RECIPIENT-DERIVED REGULATORY DENDRITIC CELLS FOR THERAPY OF GRAFT REJECTION
The first reports suggesting that DCreg of donor origin could be used to inhibit allograft rejection appeared in 1995/1996 [54, 55] . Subsequently, many reports have shown that donor-derived DCreg or syngeneic/autologous DCreg (either pulsed or unpulsed with donor antigen) infused alone or together with an immunosuppressive agent(s) can induce indefinite organ allograft survival/donorspecific tolerance in rodents [10, 56] . In more recent studies in a preclinical, MHC-mismatched nonhuman primate (NHP) renal allograft model, graft survival was prolonged significantly in rhesus macaques given VitD3-and IL-10-conditioned DCreg 1 week before transplant, in combination with a minimal immunosuppressive regimen of costimulation blockade and rapamycin [57] . No evidence of host sensitization (donor-specific antibodies) was observed. Median graft survival time was also prolonged in this model when autologous DCreg pulsed with donor antigen (cell membrane microvesicles) were infused a day before transplantation [ 
INNOVATIVE APPROACHES TO COMBINATION THERAPY
Many pharmacologic and biologic agents promote dendritic cell tolerogenicity in rodents [42] . Following observations that exosomes derived from immature donor dendritic cells (immDex) prolonged experimental graft survival and that their effects were associated with Treg, Ma et al. [61 & ] combined the exosomes with donor antigen-specific Treg and achieved tolerance without immunosuppressive therapy in a rat liver allograft model. The immDex amplified Treg in vivo most likely through binding/ fusing with host dendritic cells and being presented by these dendritic cells, which could be augmented by IL-2 administration. Also, in a rat liver allograft model, combined infusion of donor-derived immature dendritic cells and CD4
þ Treg, 7 days before transplantation, was more effective than either regulatory cell population alone and appeared to maintain a feedback loop between the DCreg and Treg in vivo [62] .
CLINICAL TRIALS OF REGULATORY DENDRITIC CELL THERAPY IN RENAL AND LIVER TRANSPLANTATION
The potential of DCreg for the prevention of rejection after clinical solid organ transplantation has been discussed extensively in recent reviews [17 & ,63] . Clinical trials of DCreg therapy in renal or liver transplantation have begun in Europe and the United States. Autologous DCreg infusion, 1 day before transplant, is under examination at the University of Nantes, France, in live donor renal transplantation with standard of care (SOC) triple drug immunosuppressive (azathioprine, steroid, tacrolimus) (Clinical Trials.gov Identifier: NCT0225055 [64] ). An NIH-supported clinical trial to test the safety of donor-derived DCreg infusion in living donor renal transplantation will begin at the University of Pittsburgh, the United States in 2018 [65] .
The possibility that DCreg administration as a novel adjunct induction therapy may promote immunological mechanisms conducive to induction of donor-specific T cell hyporesponsiveness (tolerance) and enable early withdrawal of all immunosuppressives after liver transplantation carries the potential important advantage of sparing patients the side-effects of long-term immunosuppressive therapy, particularly CNI. Recently, in a multicenter study of early posttransplant immunosuppressive drug withdrawal (CNI-based therapy; no induction) in liver transplantation [66] , immunosuppressive minimization starting 12-14 months posttransplant was tolerated by the majority of patients, whereas complete immunosuppressive withdrawal was achieved in 13% of those that qualified for the minimization protocol. This degree of success provides a potential basis for assessment of the impact of innovative strategies, including DCreg infusion, aimed at improving the incidence of well-tolerated withdrawal of immunosuppressive therapy and operational tolerance in human liver transplantation.
At the University of Pittsburgh, a first-inhuman, single center, open-label, phase I/II study (NCT03164265) to test the safety and preliminary efficacy of a single infusion of donor-derived DCreg in de novo adult living donor liver transplant recipients [67 & ] has been initiated. Patients receive SOC immunosuppressive therapy (MMF, steroid, and tacrolimus), without antibody induction. Good manufacturing practice grade DCreg are generated [68] in VitD3 and IL-10 from monocytes obtained by leukapheresis from prospective living donors and infused as induction therapy into their respective recipients, 7 days before transplant. The DCreg dose range (2.5-10 Â 10 6 /kg) corresponds to the range for which both safety and efficacy were demonstrated in the preclinical NHP renal transplant model [57] . A half dose of MMF is administered concomitant with DCreg infusion and until the time of transplant to minimize any potential risk of sensitization. In eligible patients, determined by permissive liver function tests and (at 12 months posttransplant) a permissive liver biopsy, immunosuppressive drug weaning begins at month 6 and continues through month 18. Follow-up continues for 3 years after the last dose of immunosuppressive.
CONCLUSIONS AND FUTURE PROSPECTS
Omics studies are better defining the molecules that enhance the tolerogenic phenotype, stability, and longevity of DCreg and their resistance to proinflammatory stimuli. This is likely to instruct improved and more standardized design of protocols for generation of clinical grade DCreg for therapeutic application. Strategies that target dendritic cells selectively in situ to enhance their immune regulatory function and that enhance migration of DCreg to SLO show promise for potential therapeutic application. Acquisition of donor MHC by host dendritic cells (cross-dressing) and the immune regulatory function of these cross-dressed dendritic cells in allograft recipients in relation to development of transplant tolerance is a key topic for future mechanistic studies. Clinical trials of DCreg in organ transplantation have been instigated and will provide valuable insights into the potential of these novel regulatory immune cells for improved outcomes in organ transplantation.
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